Long-acting cabotegravir PrEP: a time for cautious optimism

被引：2
|
作者：
Griffin, David W. J. [1 ,2 ]
Hoy, Jennifer F. [1 ,2 ]
McMahon, James H. [1 ,2 ,3 ]
机构：
[1] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic, Australia
[3] Monash Hlth, Dept Infect Dis, Melbourne, Vic, Australia
来源：
LANCET HIV | 2023年 / 10卷 / 12期
关键词：
HIV;
D O I：
10.1016/S2352-3018(23)00294-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E756 / E757
页数：2
相关论文
共 50 条
  • [1] Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP
    Han, Kelong
    Patel, Parul
    McCallister, Scott
    Rinehart, Alex R.
    Gandhi, Yash
    Spreen, William
    Landovitz, Raphael J.
    Delany-Moretlwe, Sinead
    Marzinke, Mark A.
    McKeon, Todd
    Budnik, Piotr
    van Wyk, Jean
    Ford, Susan L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024,
  • [2] Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon, Geoffroy
    Ghosn, Jade
    [J]. HIV MEDICINE, 2023, 24 (06) : 653 - 663
  • [3] Formulation and pharmacology of long-acting cabotegravir
    Trezza, Christine
    Ford, Susan L.
    Spreen, William
    Pan, Rennan
    Piscitelli, Stephen
    [J]. CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 239 - 245
  • [4] Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?
    Levy, Matthew E.
    Agopian, Anya
    Magnus, Manya
    Rawls, Anthony
    Opoku, Jenevieve
    Kharfen, Michael
    Greenberg, Alan E.
    Kuo, Irene
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (03) : E80 - E82
  • [5] Long-acting injectable PrEP
    Harris, Philippa
    [J]. LANCET HIV, 2020, 7 (08): : E532 - E532
  • [6] HIV PrEP Dose Rationale for Cabotegravir (GSK1265744) Long-acting Injectable Nanosuspension
    Spreen, Bill
    Rinehart, Alex
    Smith, Kimberly
    Margolis, David
    Ford, Susan
    Piscitelli, Steve
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A12 - A12
  • [7] A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP
    Yu, Yifan
    Bigos, Kristin L.
    Marzinke, Mark A.
    Landovitz, Raphael J.
    McCauley, Marybeth
    Ford, Susan
    Hendrix, Craig W.
    Bies, Robert R.
    Weld, Ethel D.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (10) : 4623 - 4632
  • [8] Long-Acting Cabotegravir for HIV/AIDS Prophylaxis
    Engelman, Kathleen D.
    Engelman, Alan N.
    [J]. BIOCHEMISTRY, 2021, 60 (22) : 1731 - 1740
  • [9] Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV
    Philbin, Morgan M.
    Perez-Brumer, Amaya
    [J]. CURRENT OPINION IN HIV AND AIDS, 2022, 17 (02) : 72 - 88
  • [10] Long-Acting PrEP Shows Promise
    Kuehn, Bridget M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (07): : 621 - 621
12345